|
1. Biology and Pathophysiology of Chronic Myelogenous Leukemia1. Biology and Pathophysiology of Chronic Myelogenous Leukemia
|
by
Dr Giuseppe Saglio
Chronic myelogenous leukemia (CML) is a myeloproliferative disease characterized by the presence of a specific cytogenetic abnormality, the Philadelphia (Ph) chromosome
...
Learn More
|
CME Credits
2.00
AMA PRA
Category 1 Credits™
|
|
|
2. Clinical Manifestations and Laboratory Studies2. Clinical Manifestations and Laboratory Studies
|
by
Dr Michael Mauro
Of the nearly 5000 cases of CML diagnosed each year, approximately 90% of patients are diagnosed in the chronic phase (CP)
...
Learn More
|
CME Credits
1.50
AMA PRA
Category 1 Credits™
|
|
|
3. Current Treatment of Chronic Myelogenous Leukemia – Imatinib and Allogeneic SCT3. Current Treatment of Chronic Myelogenous Leukemia – Imatinib and Allogeneic SCT
|
by
Dr Jorge Cortes
Over the course of the last several years, imatinib mesylate, a tyrosine kinase inhibitor, has dramatically altered the treatment of chronic myelogenous leukemia (CML)
...
Learn More
|
CME Credits
1.00
AMA PRA
Category 1 Credits™
|
|
|
4. Mechanisms of Resistance4. Mechanisms of Resistance
|
by
Dr Michael Deininger
Primary resistance is defined as the failure of a patient to attain a predefined level of response, eg, a complete hematologic response (CHR) or CCyR
...
Learn More
|
CME Credits
2.50
AMA PRA
Category 1 Credits™
|
|
|
5. Treatment of Imatinib Resistant Chronic Myelogenous Leukemia5. Treatment of Imatinib Resistant Chronic Myelogenous Leukemia
|
by
Dr Hagop Kantarjian
Chronic myelogenous leukemia was the first neoplastic disease for which a direct chromosomal link was identified
...
Learn More
|
CME Credits
1.50
AMA PRA
Category 1 Credits™
|
|
|
6. Monitoring of Treatment of Chronic Myelogenous Leukemia6. Monitoring of Treatment of Chronic Myelogenous Leukemia
|
by
Dr Andreas Hochhaus
Chronic myelogenous leukemia (CML) constitutes a clinical model for molecular detection and monitoring for disease progression and therapeutic efficacy
...
Learn More
|
CME Credits
2.00
AMA PRA
Category 1 Credits™
|
|
|
7. Chronic Myelogenous Leukemia Treatment Guidelines7. Chronic Myelogenous Leukemia Treatment Guidelines
|
by
Dr Susan O'Brien and Dr Elias Jabbour
Treatment guidelines in CML focus on patients for whom imatinib therapy has failed. A number of studies suggest, however, that earlier responses to imatinib therapy
...
Learn More
|
CME Credits
1.00
AMA PRA
Category 1 Credits™
|
|
|
8. Questions on Management and Treatment: Side Effects and Drug Interactions8. Questions on Management and Treatment: Side Effects and Drug Interactions
|
by
Dr Elias Jabbour
The introduction of imatinib has marked an important and revolutionary step in the management of chronic myelogenous leukemia (CML)
...
Learn More
|
CME Credits
1.50
AMA PRA
Category 1 Credits™
|
|